• 1
    Partin AW,Yoo J,Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150: 110-114.
  • 2
    Catalona WJ,Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998; 160: 2428-2434.
  • 3
    Kupelian PA,Elshaikh M,Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002; 20: 3376-3385.
  • 4
    Soloway MS,Sharifi R,Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995; 154: 424-428.
  • 5
    Goldenberg SL,Klotz LH,Srigley J, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996; 156: 873-877.
  • 6
    Beer TM,Garzotto M,Lowe BA, et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2004; 10: 1306-1311.
  • 7
    Eastham JA,Kelly WK,Grossfeld GD,Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003; 62( suppl 1): 55-62.
  • 8
    Febbo PG,Richie JP,George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005; 11: 5233-5240.
  • 9
    Dreicer R,Magi-Galluzzi C,Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004; 63: 1138-1142.
  • 10
    Oh WK,George DJ,Kaufman DS, et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol. 2001; 28: 40-44.
  • 11
    Ryan CJ,LaTulippe E,Kotsianti A, et al. Identification of drug targets in prostate cancers treated with neoadjuvant hormone therapy prior to radical prostatectomy by mRNA microarrays. Proc Am Soc Clin Oncol. 2002; 21. Abstract 700.
  • 12
    Barton J,Blackledge G,Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001; 58: 114-122.
  • 13
    Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001; 28: 3-7.
  • 14
    Sirotnak FM,Zakowski MF,Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000; 6: 4885-4892.
  • 15
    Manegold C,Gatzemeier U,Averbuch S,Fandi A. An open label, pilot trial of 2 doses of ZD1839 in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): preliminary safety results. Ann Oncol. 2002; 13: 149.
  • 16
    Tamura T,Nakagawa K,Fukuoka M, et al. A phase I intermittent dose-escalation trial of ZD1839 (‘Iressa’) in Japanese patients with solid malignant tumors. Lung Cancer. 2000; 29( suppl 1): 71.
  • 17
    Walsh PC,Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982; 128: 492-497.
  • 18
    Kattan MW,Eastham JA,Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 766-771.
  • 19
    Petrylak DP,Tangen CM,Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
  • 20
    Tannock IF,de Wit R,Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
  • 21
    Garzotto M,Myrthue A,Higano CS,Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol. 2006; 24: 254-259.
  • 22
    Vlahovic G,Crawford J. Activation of tyrosine kinases in cancer. Oncologist. 2003; 8: 531-538.
  • 23
    Small EJ,Fontana J,Tannir N, et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007; 100: 765-769.
  • 24
    Canil CM,Moore MJ,Winquist E, et al. Randomized phase II study of 2 doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 2005; 23: 455-460.
  • 25
    Wilding G,Soulie P,Trump D, et al. Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006; 106: 1917-1924.
  • 26
    Salzberg M,Rochlitz C,Morant R, et al. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie. 2007; 30: 355-360.
  • 27
    Sachelarie I,Grossbard ML,Chadha M,Feldman S,Ghesani M,Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006; 11: 574-589.